ABSTRACT The cardiovascular and hypokalaemic effects of equal doses of inhaled fenoterol, isoprenaline and salbutamol were compared in eight healthy male volunteers, in a double blind, placebo controlled study. Increasing doses of 400, 600, and 800 Mg were given from a metered dose inhaler at 15 minute intervals, followed by measurements of heart rate, blood pressure, total electromechanical systole (as a measure of inotropic response), QTc interval, and plasma potassium concentration. After repeated inhalation, fenoterol resulted in significantly greater chronotropic, electrocardiographic, and hypokalaemic effects than either isoprenaline or salbutamol. The maximum inotropic effect of fenoterol was similar to that of isoprenaline.
Introduction
As a result ofconcern that isoprenaline may have been responsible for the rise in asthma mortality in several countries in the 1960s' several beta2 adrenergic agonist drugs were developed. Inhaled beta2 agonists are now the most widely used treatment for asthma in New Zealand.2 Although these agents have been shown to have a greater selectivity ratio3 (that is, ratio of bronchodilator effect to chronotropic effect for a given intravenous dose), little work has been done to compare their cardiac effects with those of isoprenaline administered by the inhaled route in man. Since their introduction there have been reports of arrhythmias in some patients4" and aggravation of angina in those with ischaemic heart disease.67
Over the last decade mortality from asthma has again increased in some countries, in particular New Zealand.8 As a result ofdetailed investigations into the causes of this increase in mortality in New Zealand, one of the recommendations of the Ministerial Asthma Task Force was that "the relationship between the trends in asthma mortality and anti-asthma medication requires further investigation."9 An International Asthma Mortality Task Force has subsequently recommended that "further information is needed about the deleterious side effects of antiasthma medications used alone and in combination."'0
In response to these recommendations we have compared the cardiovascular effects of isoprenaline with those of fenoterol, salbutamol, and placebo. Salbutamol All subjects were medical personnel familiar with the use ofmetered dose inhalers and all were instructed in a standard technique of inhalation. The inhaler was held in the mouth and subjects were asked to inhale slowly from functional residual capacity to total lung capacity, and to actuate the inhaler just after the onset of inspiration. They were instructed to hold their breath for three seconds after inhalation and then to exhale slowly. The study was not begun until the investigator was satisfied with the adequacy and reproducibility of the inhaler technique. QS2 was measured as previously described,'4 and corrected for heart rate according to an equation developed in our laboratory: QS2I = QS2 + 1 2 x HR (QS2I is the QS2 index, corrected for heart rate). 5 Briefly, measurement is made from the onset of the Q wave of the high speed ECG to the initial high frequency recording of the second heart sound. The ECG and phonocardiogram are recorded photographically on paper at 100 mm/s from an oscilloscope trace. From the ECG the QT interval was measured by extrapolating the descending slope of the T wave to the baseline (horizontal line joining the P-P interval). The QT interval was corrected for heart rate by means of the Bazett formula. '6 Blood pressure was mesured with an automatic cuff (Vita-Stat).
ANALYSIS
Statistical analysis was undertaken by means of the SAS statistical package. A fourway analysis of variance for repeated measures'7 was performed, on change from control data, with subject, treatment, time and group effects being analysed. The significance level was adjusted for multiple comparisons by using Bonferroni's inequality'8 (p < 0-05/number of comparisons). Hence a probability value of p < 0-0028 was considered significant for changes in plasma potassium, and p < 0-0014 for all other values.
Results
There were no significant differences between the subjects' control measurements on any of the four study days (table 1) . For fenoterol and isoprenaline, the measurements that followed the 800 pg dose represent the mean for seven subjects, as one subject was withdrawn on both occasions after an acute rise in sytolic blood pressure to > 160 mm Hg after the 600 pg dose. The change in heart rate and QS2I from baseline for the three doses ofbeta agonist and placebo are shown in -9) 1 1 2t (2.4) 2-8t (2 8) 2 9t (1 9) 8-4 (2.4 inotropic effect of terbutaline was significantly attenuated by the beta, selective antagonist atenolol. The maximum inotropic effect of fenoterol will represent a cumulative effect, since fenoterol is cleared much less rapidly than isoprenaline. The difference in inotropic effect between fenoterol and salbutamol indicates the greater beta, adrenergic activity of fenoterol and supports earlier animal studies23 and more recent studies in normal subjects. '3 The increase in heart rate after administration ofthe beta agonists in this study is likely to be due to a Table 3 Effect ofinhaling increasing p < 0 0011, #p < 0-001, **p < 00001 versus placebo;
with Bonferroni correction p < 0-0028 considered sign ificant.
combination of beta, and beta2 adrenoceptor stimulation. Regardless of the mechanism, an increase in heart rate combined with an increase in inotropy will result in increased myocardial oxygen consumption, which in the face of hypoxaemia may be deleterious.24 It has been previously found that beta2 adrenergic agonists cause hypokalaemia owing to a direct cellular uptake of potassium through increased Na-K ATPase activity. 25 Our observations that the reduction in plasma potassium due to fenoterol was more than double that of salbutamol is in keeping with the study of Scheinin et al'3 and provides further evidence that there are significant differences in the pharmacodynamic effects of these two agents when given in equal doses.
Both hypokalaemia and beta adrenergic stimulation are associated with electrophysiological changes in cardiac muscle. In this study fenoterol caused a significantly greater prolongation of the QTc interval than either isoprenaline or salbutamol. QTc prolongation may be associated with ventricular dysrhythmias,26 and Tandon has shown that repeated inhalation of fenoterol was associated with a greater frequency of ventricular ectopic beats than equivalent doses of salbutamol. 27 It could be argued that both the doses and the dosing interval that we have used are excessive and certainly they exceed the manufacturers recommended ranges. In the context ofacute severe asthma relatively unresponsive to bronchodilator treatment, however, we believe that such self administered doses may be used.
In summary, we have shown that repeated inhalation of fenoterol in normal volunteers results in significantly greater cardiovascular and hypokalaemic effects than the same doses of salbutamol while being similar in its maximum inotropic effect to isoprenaline. The relevance of these findings in patients with severe asthma remains to be clarified.
